05 March 2013
A drug could help control the side effects of overactive bladder (OAB), a new report shows.
Mirabegron was found to reduce the frequency of incontinence episodes and number of daily urinations, by researchers in the US.
The study, published in the Journal of Urology, also found that mirabegron improved urgency and nocturia – the need to get up in the night to urinate – in adults with overactive bladder compared to those in a placebo group.
Dr Victor Nitti, of the Langone Medical Center in New York, said: "With its balanced efficacy, safety, and tolerability profile, mirabegron could provide an alternative therapeutic option for OAB, particularly in patients whose OAB is inadequately addressed by current antimuscarinic therapy."
A study published last month established a greater understanding of how the body knows when the bladder is full.
It is thought as many as six million people in the UK have some degree of urinary incontinence, with women likely to be twice as affected as men.
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare